Researchers at Mount Sinai have identified RNA biomarkers in blood-based nanoparticles called SECmeres that can distinguish Alzheimer's disease from healthy controls. Published in Nature Communications, the findings could pave the way for a minimally invasive, PCR-style blood test for earlier Alzheimer's diagnosis — potentially catching the disease before proteins or pathology are even detectable.
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered a new class of blood-based biomarkers that could transform how Alzheimer's disease is diagnosed. Their study, published in Nature Communications, found that tiny brain-derived nanoparticles called SECmeres carry RNA signatures specific to Alzheimer's — and that these RNA markers can distinguish Alzheimer's patients from healthy controls more effectively than those found in small extracellular vesicles (EVs), while large EVs showed no differences at all.
The key insight: current biomarker research largely analyzes whole blood, which may miss disease-specific signals locked inside heterogeneous particle subpopulations. By isolating and characterizing these EVP subpopulations, the team identified distinct RNA signatures — including markers like neurogranin and syntaxin in SECmeres — that may reflect disease changes earlier in the process, before traditional protein biomarkers like p-tau217 or amyloid ratios become detectable.
Key Takeaways:
Why it matters: With Alzheimer's affecting millions globally, earlier and easier diagnosis is a critical unmet need. A simple blood-based RNA test could dramatically expand access to timely diagnosis and open new doors for monitoring disease progression and treatment response.
